RU2016124538A - Антагонисты гастрина для лечения и профилактики остеопороза - Google Patents
Антагонисты гастрина для лечения и профилактики остеопороза Download PDFInfo
- Publication number
- RU2016124538A RU2016124538A RU2016124538A RU2016124538A RU2016124538A RU 2016124538 A RU2016124538 A RU 2016124538A RU 2016124538 A RU2016124538 A RU 2016124538A RU 2016124538 A RU2016124538 A RU 2016124538A RU 2016124538 A RU2016124538 A RU 2016124538A
- Authority
- RU
- Russia
- Prior art keywords
- hypergastrinemia
- individual
- gastrin receptor
- receptor
- agent
- Prior art date
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims 2
- 239000005557 antagonist Substances 0.000 title claims 2
- 102100021022 Gastrin Human genes 0.000 title 1
- 108010052343 Gastrins Proteins 0.000 title 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims 16
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 claims 11
- 102000052874 Gastrin receptors Human genes 0.000 claims 11
- 206010060377 Hypergastrinaemia Diseases 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 210000000988 bone and bone Anatomy 0.000 claims 3
- 206010033165 Ovarian failure Diseases 0.000 claims 2
- 239000003743 cholecystokinin B receptor antagonist Substances 0.000 claims 2
- 230000002611 ovarian Effects 0.000 claims 2
- 201000004535 ovarian dysfunction Diseases 0.000 claims 2
- 231100000539 ovarian failure Toxicity 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 238000001050 pharmacotherapy Methods 0.000 claims 1
- 229940126409 proton pump inhibitor Drugs 0.000 claims 1
- 239000000612 proton pump inhibitor Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (16)
1. Способ лечения заболевания или состояния костей, связанного с гипергастринемией, у нуждающегося в этом индивидуума, включающий введение индивидууму по меньшей мере одной дозы терапевтически эффективного количества направленно воздействующего на рецептор гастрина средства, таким образом проводя лечение заболевание или состояния костей, связанного с гипергастринемией.
2. Способ по п. 1, где направленно воздействующее на рецептор гастрина средство вводят в течение периода времени лечения до разрешения заболевания или состояние костей, связанного с гипергастринемией.
3. Способ по п. 1, где индивидууму вводят по меньшей мере одну дозу направленно воздействующего на рецептор гастрина средства в течение периода продолжительности гипергастринемии, независимо от причины гипергастринемии.
4. Способ по п. 1, где заболевание или состояние костей, связанное с гипергастринемией, представляет собой заболевание или состояние, характеризуемое как остеопороз.
5. Способ по п. 1, где направленно воздействующее на рецептор гастрина средство представляет собой селективный антагонист рецептора CCK2.
6. Способ по п. 5, где селективный антагонист рецептора CCK2 представляет собой YF476.
7. Способ по п. 1, где индивидуум представляет собой женщину со сниженной овариальной функцией или недостаточностью яичников.
8. Способ по п. 1, где индивидуум: (a) представляет собой женщину со сниженной овариальной функцией или недостаточностью яичников и (b) страдает гипергастринемией.
9. Способ по п. 1, дополнительно включающий введение направленно воздействующего на рецептор гастрина средства с терапевтически эффективным количеством ингибитора протонной помпы (PPI) или антагониста рецепторов гистамина 2 (H2R) одномоментно или последовательно в любом порядке.
10. Способ по п. 1, где терапевтически эффективное количество направленно воздействующего на рецептор гастрина средства представляет собой 10-25 наномоль.
11. Способ по п. 8, где гипергастринемия представляет собой неопластическую гипергастринемию или гипергастринемию, связанную с фармакотерапией, подавляющей кислоту.
12. Способ по п. 10, где терапевтически эффективное количество направленно воздействующего на рецептор гастрина средства составляет 0,2-14 мкг/кг массы тела индивидуума.
13. Способ по п. 1, где направленно воздействующее на рецептор гастрина средство вводят индивидууму в однократной дозе посредством подкожной инъекции.
14. Способ по п. 1, где направленно воздействующее на рецептор гастрина средство вводят индивидууму посредством внутривенной инъекции.
15. Способ по п. 1, где направленно воздействующее на рецептор гастрина средство вводят индивидууму перорально в дозе в диапазоне 20-100 мг.
16. Способ по п. 9, где PPI или антагонист H2R вводят перорально индивидууму.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907980P | 2013-11-22 | 2013-11-22 | |
| US61/907,980 | 2013-11-22 | ||
| PCT/US2014/066832 WO2015077572A1 (en) | 2013-11-22 | 2014-11-21 | Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016124538A true RU2016124538A (ru) | 2017-12-27 |
| RU2693484C1 RU2693484C1 (ru) | 2019-07-03 |
Family
ID=52118000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016124538A RU2693484C1 (ru) | 2013-11-22 | 2014-11-21 | Антагонисты гастрина для лечения и профилактики остеопороза |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10709714B2 (ru) |
| EP (1) | EP3071206B1 (ru) |
| JP (1) | JP6502939B2 (ru) |
| KR (1) | KR102254957B1 (ru) |
| CN (1) | CN106163527A (ru) |
| AU (1) | AU2014352875B2 (ru) |
| BR (1) | BR112016011727A2 (ru) |
| CA (1) | CA2929858C (ru) |
| DK (1) | DK3071206T3 (ru) |
| ES (1) | ES2870538T3 (ru) |
| MX (1) | MX2016006657A (ru) |
| PL (1) | PL3071206T3 (ru) |
| RU (1) | RU2693484C1 (ru) |
| WO (1) | WO2015077572A1 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10881667B2 (en) | 2018-10-30 | 2021-01-05 | City University Of Hong Kong | Method and composition for treating epilepsy |
| US11285161B2 (en) | 2019-04-26 | 2022-03-29 | City University Of Hong Kong | Method and composition for treating mental disorder and pain associated with nerve damage |
| CN110935005A (zh) * | 2019-11-19 | 2020-03-31 | 宁波大学 | 一种丙谷二肽的新用途 |
| CN115770266B (zh) * | 2023-01-30 | 2023-05-09 | 云南中医药大学 | 一种用于治疗绝经后骨质疏松的药物组合物 |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989005812A1 (fr) | 1987-12-22 | 1989-06-29 | Yoshitomi Pharmaceutical Industries, Ltd. | Composes de thienodiazepine et leur utilisation en medecine |
| DE69017302T3 (de) | 1989-08-04 | 1999-08-05 | Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire | Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten. |
| US5399565A (en) | 1990-07-17 | 1995-03-21 | Eli Lilly And Company | Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof |
| HUT67299A (en) | 1990-12-25 | 1995-03-28 | Yamanouchi Pharma Co Ltd | Novel benzodiazepine derivetives, pharmaceutical compositions contaning them and process for their producing |
| CZ282536B6 (cs) | 1991-07-12 | 1997-08-13 | Warner-Lambert Company | Nepřirozený dipeptoid pro výrobu léčiva pro prevenci a léčbu záchvatů panického strachu |
| CA2120939A1 (en) | 1991-10-11 | 1993-04-15 | Tetsuya Tahara | Therapeutic agent for osteoporosis and diazepine compound |
| AU3247593A (en) * | 1991-12-20 | 1993-07-28 | Warner-Lambert Company | Therapeutic combinations useful in the treatment of gastroesophageal reflux disease |
| IL104853A (en) | 1992-02-27 | 1997-11-20 | Yamanouchi Pharma Co Ltd | Benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them |
| JP3419539B2 (ja) | 1993-02-17 | 2003-06-23 | 中外製薬株式会社 | インドリン−２−オン誘導体 |
| GB2282595A (en) | 1993-08-25 | 1995-04-12 | Yamanouchi Pharma Co Ltd | Benzodiazepine derivatives |
| IT1261255B (it) | 1993-09-09 | 1996-05-09 | Rotta Research Lab | Derivati acidi poliamidici ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico. |
| EP0869975B1 (en) | 1995-12-11 | 2007-08-15 | New England Medical Center Hospitals, Inc. | Assay for and uses of peptide hormone receptor ligands |
| US5750353A (en) | 1995-12-11 | 1998-05-12 | New England Medical Center Hospitals, Inc. | Assay for non-peptide agonists to peptide hormone receptors |
| US5922883A (en) | 1996-04-03 | 1999-07-13 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US20040001842A1 (en) | 1997-05-12 | 2004-01-01 | Dov Michaeli | Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors |
| ES2227833T3 (es) | 1997-05-12 | 2005-04-01 | Aphton Corporation | Composiciones inmunogenicas para el receptor cck-b/gastrina y metodos para el tratamiento de tumores. |
| EP1076561B1 (en) | 1998-05-15 | 2005-03-30 | Aphton Corporation | Combination therapy for the treatment of tumors |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| IL139811A0 (en) | 1998-06-04 | 2002-02-10 | Abbott Lab | Cell adhesion-inhibiting antinflammatory compounds |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| DE60016384T2 (de) | 1999-01-29 | 2005-12-01 | Chugai Seiyaku K.K. | Chondrogonese promotoren und indolin-2-on derivate |
| WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| US20030191279A1 (en) | 1999-08-27 | 2003-10-09 | Goldstein Steven Wayne | Urea derivatives useful as anticancer agents |
| US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| ES2259617T3 (es) | 1999-11-05 | 2006-10-16 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Compuestos heterociclicos y su aplicacion como medicamentos. |
| WO2001035899A2 (en) | 1999-11-19 | 2001-05-25 | Axxima Pharmaceuticals Ag | Inhibitors of helicobacter pylori induced gastrointestinal diseases |
| AU2001253024A1 (en) | 2000-04-10 | 2001-10-23 | The General Hospital Corporation | Diagnosis and treatment of gastrointestinal disease |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| AU2002252456A1 (en) | 2001-03-23 | 2002-10-08 | Aphton Corporation | Combination treatment of pancreatic cancer |
| EP1391211A1 (en) | 2001-04-27 | 2004-02-25 | Chugai Seiyaku Kabushiki Kaisha | Chondrogenesis promoters |
| US20090191232A1 (en) | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
| CA2445477A1 (en) | 2001-05-11 | 2002-11-21 | Yamanouchi Pharmaceutical Co., Ltd. | Antitumor agents |
| AUPR738301A0 (en) | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
| CN100348196C (zh) | 2001-11-13 | 2007-11-14 | 詹姆士布莱克基金会有限公司 | 作为胃泌激素和缩胆囊肽受体配体的苯并三氮杂䓬 |
| EP1478357B1 (en) | 2002-02-19 | 2007-01-31 | Pfizer Italia S.r.l. | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents |
| DE10207037A1 (de) | 2002-02-20 | 2003-08-28 | Bayer Cropscience Gmbh | 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| UA79804C2 (en) | 2002-07-03 | 2007-07-25 | Janssen Pharmaceutica Nv | Cck-1 receptor modulators |
| US20030049698A1 (en) | 2002-10-08 | 2003-03-13 | Wang Timothy C. | Diagnosis and treatment of gastrointestinal disease |
| CA2520546A1 (en) | 2003-03-28 | 2005-02-10 | Janssen Pharmaceutica, N.V. | Benzo[1,2,5]thiadiazole compounds |
| GB0310865D0 (en) | 2003-05-12 | 2003-06-18 | Black James Foundation | Gastrin and cholecystokinin receptor ligands |
| WO2004101533A1 (en) | 2003-05-12 | 2004-11-25 | Janssen Pharmaceutica, N.V. | 1, 3, 4-benzotriazepin-2-one salts and their use as cck receptor ligands |
| WO2005007107A2 (en) * | 2003-07-11 | 2005-01-27 | University Of Massachusetts | Histamine and cck2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer |
| CA2534887A1 (en) | 2003-08-08 | 2005-02-24 | Janssen Pharmaceutica, N.V. | Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds |
| US20070293482A1 (en) | 2004-03-19 | 2007-12-20 | Novartis Pharmaceuticals Corporation | Process for Preparing Benzodiazepines |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US7947833B2 (en) | 2004-08-04 | 2011-05-24 | Janssen Pharmaceutica Nv | Preparation of quinoxaline compounds |
| MX2007003623A (es) | 2004-09-24 | 2007-09-11 | Johnson & Johnson | Compuestos sulfonamida. |
| EP1817333A4 (en) | 2004-10-12 | 2008-12-31 | Janssen Pharmaceutica Nv | CHOLECYSTOKININ-1 RECEPTOR MATERIALS OF DOGS AND THEIR USE |
| WO2006049941A2 (en) | 2004-10-27 | 2006-05-11 | Neurogen Corporation | Diaryl ureas as cb1 antagonists |
| WO2006052542A2 (en) | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Arylalkyl ureas as cb1 antagonists |
| GB0425196D0 (en) | 2004-11-15 | 2004-12-15 | Black James Foundation | Gastrin and cholecystokinin receptor ligands |
| WO2006064339A1 (en) | 2004-12-17 | 2006-06-22 | Pfizer Japan Inc. | Chromane derivatives useful as acid pump antagonists |
| US20080161293A1 (en) | 2005-01-19 | 2008-07-03 | Zeria Pharmaceutical Co., Ltd. | Antitumor Agent |
| AR053713A1 (es) | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
| JP5197361B2 (ja) | 2005-06-06 | 2013-05-15 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ | 睡眠障害を処置するための組成物および方法 |
| WO2006134460A1 (en) | 2005-06-14 | 2006-12-21 | Pfizer Japan Inc. | Chromane substituted benzimidazole derivatives as acid pump antagonists |
| DE602005013372D1 (de) | 2005-07-29 | 2009-04-30 | Rottapharm Spa | Kombination aus Itriglumid und PPI zur Behandlung von gastrointestinalen- und assozierten Krankheiten |
| WO2007026218A2 (en) | 2005-09-01 | 2007-03-08 | Pfizer Japan Inc. | Chromane substituted 2-alkyl imidazopyridine derivatives and use thereof as acid pump antagonists |
| WO2007031860A1 (en) | 2005-09-15 | 2007-03-22 | Pfizer Japan Inc. | Indane substituted benzimidazoles and their use as acid pump inhibitors |
| WO2007072142A2 (en) | 2005-12-19 | 2007-06-28 | Pfizer Japan Inc. | Benzimidazole-5-carboxamide derivatives |
| BR122020004679B1 (pt) | 2005-12-19 | 2021-09-21 | Raqualia Pharma Inc | Composição farmacêutica |
| KR20080108129A (ko) | 2006-03-17 | 2008-12-11 | 라퀄리아 파마 인코포레이티드 | 크로메인 유도체 |
| EP2004631A1 (en) | 2006-04-12 | 2008-12-24 | Merck Patent GmbH | N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases |
| FR2901472B1 (fr) | 2006-05-24 | 2010-08-13 | Oreal | Procede de defrisage des fibres keratiniques avec un moyen de chauffage et des agents denaturants |
| FR2901473B1 (fr) | 2006-05-24 | 2010-08-13 | Oreal | Procede de defrisage des fibres keratiniques avec un moyen de chauffage et une amide |
| WO2008035195A1 (en) | 2006-09-21 | 2008-03-27 | Raqualia Pharma Inc. | Benzimidazole derivatives as selective acid pump inhibitors |
| WO2008046082A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of heterocyclic compounds as therapeutic agents |
| WO2008059373A1 (en) | 2006-11-17 | 2008-05-22 | Raqualia Pharma Inc. | Imidazo [1, 2-a] pyrazine derivatives and their use as acid pump antagonists |
| JP2008222557A (ja) | 2007-03-08 | 2008-09-25 | Kotobuki Seiyaku Kk | ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物 |
| WO2008114123A1 (en) | 2007-03-21 | 2008-09-25 | Raqualia Pharma Inc. | Spiro benzimidazole derivatives as acid pump inhibitors |
| WO2008124524A2 (en) | 2007-04-03 | 2008-10-16 | Janssen Pharmaceutica N.V. | Aryl sulfonamide compounds as modulators of the cck2 receptor |
| WO2008124518A1 (en) | 2007-04-03 | 2008-10-16 | Janssen Pharmaceutica N.V. | Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor |
| JP5492770B2 (ja) | 2007-06-26 | 2014-05-14 | サノフイ | ベンゾイミダゾール及びアザベンゾイミダゾールの位置選択的銅触媒合成 |
| RU2379043C2 (ru) | 2007-08-02 | 2010-01-20 | Закрытое акционерное общество "Биологические исследования и системы" | Фармацевтическая композиция для профилактики и лечения остеопороза у женщин в период менопаузы |
| WO2009020768A1 (en) | 2007-08-07 | 2009-02-12 | President And Fellows Of Harvard College | Targeting the oncoprotein nucleophosmin |
| TW201011009A (en) | 2008-09-15 | 2010-03-16 | Priaxon Ag | Novel pyrrolidin-2-ones |
| WO2010036316A1 (en) | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
| BRPI1009145A2 (pt) | 2009-03-31 | 2016-04-19 | Zeria Pharm Co Ltd | método para a fabricação de derivado de benzodiazepina |
| MX2012000275A (es) | 2009-07-09 | 2012-02-08 | Raqualia Pharma Inc | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. |
| CA2775204A1 (en) | 2009-09-24 | 2011-03-31 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Fused imidazo [3, 2 - d] pyraz ines as pi3 kinase inhibitors |
| RU2017109664A (ru) | 2009-10-06 | 2019-01-23 | Милленниум Фармасьютикалз, Инк. | Гетероциклические соединения, используемые в качестве ингибиторов pdk1 |
| AU2010319298B2 (en) | 2009-11-13 | 2015-11-05 | Plastipak Packaging, Inc. | Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions |
| WO2011063164A2 (en) | 2009-11-18 | 2011-05-26 | Steady Sleep Rx Co., Inc. | Sustained release cannabinoid medicaments |
| WO2011133722A2 (en) | 2010-04-23 | 2011-10-27 | Kineta, Inc. | Anti-viral compounds |
| US9000054B2 (en) | 2010-08-12 | 2015-04-07 | Senomyx, Inc. | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer |
| US20120231083A1 (en) | 2010-11-18 | 2012-09-13 | The Board Of Trustees Of The University Of Illinois | Sustained release cannabinoid medicaments |
| EP2640379A4 (en) | 2010-11-18 | 2014-08-13 | Pier Pharmaceuticals | LOW DOSED CANNABINOIDARY MEDICINES |
| WO2012080729A2 (en) | 2010-12-14 | 2012-06-21 | Electrophoretics Limited | CASEIN KINASE 1δ (CK1δ) INHIBITORS |
| WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| WO2013017479A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| RU2634708C9 (ru) | 2011-11-07 | 2018-05-11 | Массачусетс Инститьют Оф Текнолоджи | Оксоалкилиденовые комплексы вольфрама для z-селективного метатезиса олефинов |
| WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
| WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| TWI610916B (zh) | 2012-08-03 | 2018-01-11 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用 |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
-
2014
- 2014-11-21 MX MX2016006657A patent/MX2016006657A/es unknown
- 2014-11-21 ES ES14815149T patent/ES2870538T3/es active Active
- 2014-11-21 CA CA2929858A patent/CA2929858C/en active Active
- 2014-11-21 BR BR112016011727A patent/BR112016011727A2/pt not_active Application Discontinuation
- 2014-11-21 AU AU2014352875A patent/AU2014352875B2/en active Active
- 2014-11-21 PL PL14815149T patent/PL3071206T3/pl unknown
- 2014-11-21 RU RU2016124538A patent/RU2693484C1/ru active
- 2014-11-21 CN CN201480073822.0A patent/CN106163527A/zh active Pending
- 2014-11-21 US US14/550,233 patent/US10709714B2/en active Active
- 2014-11-21 KR KR1020167015759A patent/KR102254957B1/ko active Active
- 2014-11-21 JP JP2016533607A patent/JP6502939B2/ja active Active
- 2014-11-21 DK DK14815149.1T patent/DK3071206T3/da active
- 2014-11-21 EP EP14815149.1A patent/EP3071206B1/en active Active
- 2014-11-21 WO PCT/US2014/066832 patent/WO2015077572A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016011727A2 (pt) | 2017-08-08 |
| JP2016538295A (ja) | 2016-12-08 |
| WO2015077572A1 (en) | 2015-05-28 |
| AU2014352875A1 (en) | 2016-05-26 |
| PL3071206T3 (pl) | 2022-01-17 |
| AU2014352875B2 (en) | 2019-10-24 |
| CN106163527A (zh) | 2016-11-23 |
| US20150148339A1 (en) | 2015-05-28 |
| EP3071206A1 (en) | 2016-09-28 |
| EP3071206B1 (en) | 2021-02-17 |
| ES2870538T3 (es) | 2021-10-27 |
| KR102254957B1 (ko) | 2021-05-25 |
| DK3071206T3 (da) | 2021-05-25 |
| RU2693484C1 (ru) | 2019-07-03 |
| CA2929858A1 (en) | 2015-05-28 |
| MX2016006657A (es) | 2016-10-12 |
| JP6502939B2 (ja) | 2019-04-17 |
| CA2929858C (en) | 2022-03-29 |
| AU2014352875A8 (en) | 2016-06-30 |
| US10709714B2 (en) | 2020-07-14 |
| KR20160088891A (ko) | 2016-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dutt et al. | Skeletal muscle atrophy: potential therapeutic agents and their mechanisms of action | |
| HK1251157A1 (zh) | 使用ACTRII配体陷阱治疗β-地中海贫血 | |
| PH12018501903B1 (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| RU2016124538A (ru) | Антагонисты гастрина для лечения и профилактики остеопороза | |
| MX2019014482A (es) | Régimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruación. | |
| BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
| JP2016512564A5 (ru) | ||
| MX2023004366A (es) | Composiciones para el tratamiento de la hipertension. | |
| MX2019014483A (es) | Regimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para el tratamiento de endometriosis. | |
| EA201791227A1 (ru) | РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| WO2018027084A3 (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer | |
| RU2018123718A (ru) | Режимы дозирования мелфлуфена для раковых заболеваний | |
| HK1255584A1 (zh) | 使用阿坎酸及d-环丝胺酸的联合疗法 | |
| JP2016538295A5 (ru) | ||
| RU2020120156A (ru) | Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена | |
| EP4299120A3 (en) | Telmisartan for the prophylaxis or treatment of hypertension in cats | |
| CO2020000529A2 (es) | Metodos para tratar hiperinsulinismo congenito | |
| PH12016501026A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor | |
| WO2016130518A3 (en) | Methods and compositions for treating muscle disease and disorders | |
| MY160963A (en) | Sustained-release therapeutic agent for hypertension and renal dysfunction | |
| FI3519050T3 (fi) | Koostumuksia silmätautien hoitamiseksi | |
| RU2016145411A (ru) | Комбинация брекспипразола и налмефена, и ее применение для лечения синдрома химической зависимости | |
| RU2015133365A (ru) | Альфа-2 адренергический агонист для лечения внутриглазного давления и заболеваний глаз путем введения в стекловидное тело и внутрикамерно | |
| PH12022550917A1 (en) | Use of phenylquinolinones and flavonoid derivatives for treating neuropathic pain |